Search Results

Showing 10 from 40 results

Biosimilars are advancing more treatment options for patients

  1. USA
  2. News & Media
  3. Feature Stories
Cory Wohlbach is responsible for steering Teva s new biosimilar products through the regulatory approval process He explains what biosimilars are how they have the potential to reduce costs for patients and how patient safety is always a top priority

Biosimilars list

  1. USA
  2. Our Products

Celltrion and Teva Announce U S FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin trastuzumab

Biosimilars

Celltrion and Teva Announce U S FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan rituximab

Alvotech and Teva Announce Acceptance of U S Biologics License Application for AVT04 a Proposed Biosimilar to Stelara ustekinumab

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

Teva Announces FDA Acceptance of the Biologics License Application for Reslizumab

Teva Appoints John Nason President TAPI and Biologics Operations

Complete Response Letter Received for AVT02 Biologics License Application